» Articles » PMID: 26881131

Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain

Overview
Journal Neural Plast
Specialty Neurology
Date 2016 Feb 17
PMID 26881131
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Trisomy of human chromosome 21 in Down syndrome (DS) leads to several phenotypes, such as mild-to-severe intellectual disability, hypotonia, and craniofacial dysmorphisms. These are fundamental hallmarks of the disorder that affect the quality of life of most individuals with DS. Proper brain development involves meticulous regulation of various signaling pathways, and dysregulation may result in abnormal neurodevelopment. DS brain is characterized by an increased number of astrocytes with reduced number of neurons. In mouse models for DS, the pool of neural progenitor cells commits to glia rather than neuronal cell fate in the DS brain. However, the mechanism(s) and consequences of this slight neurogenic-to-gliogenic shift in DS brain are still poorly understood. To date, Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling has been proposed to be crucial in various developmental pathways, especially in promoting astrogliogenesis. Since both human and mouse models of DS brain exhibit less neurons and a higher percentage of cells with astrocytic phenotypes, understanding the role of JAK-STAT signaling in DS brain development will provide novel insight into its role in the pathogenesis of DS brain and may serve as a potential target for the development of effective therapy to improve DS cognition.

Citing Articles

Dysregulation of REST and its target genes impacts the fate of neural progenitor cells in down syndrome.

Huang T, Fakurazi S, Cheah P, Ling K Sci Rep. 2025; 15(1):2818.

PMID: 39843579 PMC: 11754635. DOI: 10.1038/s41598-025-87314-y.


Serotonin enhances neurogenesis biomarkers, hippocampal volumes, and cognitive functions in Alzheimer's disease.

Azargoonjahromi A Mol Brain. 2024; 17(1):93.

PMID: 39696587 PMC: 11654273. DOI: 10.1186/s13041-024-01169-4.


Neural conditional ablation of the protein tyrosine phosphatase receptor Delta PTPRD impairs gliogenesis in the developing mouse brain cortex.

Cornejo F, Franchini N, Cortes B, Elgueta D, Cancino G Front Cell Dev Biol. 2024; 12:1357862.

PMID: 38487272 PMC: 10937347. DOI: 10.3389/fcell.2024.1357862.


JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions.

Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D Mol Biomed. 2023; 4(1):40.

PMID: 37938494 PMC: 10632324. DOI: 10.1186/s43556-023-00151-1.


REST Targets JAK-STAT and HIF-1 Signaling Pathways in Human Down Syndrome Brain and Neural Cells.

Huang T, Fakurazi S, Cheah P, Ling K Int J Mol Sci. 2023; 24(12).

PMID: 37373133 PMC: 10298578. DOI: 10.3390/ijms24129980.


References
1.
Maroun L . Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. Teratology. 1995; 51(5):329-35. DOI: 10.1002/tera.1420510509. View

2.
Hasle H, Clemmensen I, Mikkelsen M . Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000; 355(9199):165-9. DOI: 10.1016/S0140-6736(99)05264-2. View

3.
Hookham M, Elliott J, Suessmuth Y, Staerk J, Ward A, Vainchenker W . The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007; 109(11):4924-9. DOI: 10.1182/blood-2006-08-039735. View

4.
Harvey R, Mullighan C, Chen I, Wharton W, Mikhail F, Carroll A . Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010; 115(26):5312-21. PMC: 2902132. DOI: 10.1182/blood-2009-09-245944. View

5.
Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View